TAU Parkinson’s Finding Could Lead to Breakthrough Drug

Under a new, exclusive agreement, international pharmaceutical company Dexcel Pharma Technologies Ltd. will develop and commercialize a cutting-edge treatment for Parkinson’s disease invented and developed at Tel Aviv University.

The novel treatment actually modifies the disease’s development, with the potential to stop its progression, as opposed to current drugs that are only able to treat its symptoms. Parkinson’s leads to the brain’s inability to control the body’s movements and is projected to affect upwards of 6 million people worldwide by 2022.

Ramot CEO Mr. Shlomo Nimrodi praised the new agreement with Dexcel, which is headquartered in Israel and has about 1,000 employees worldwide, saying that the treatment “promises to benefit millions of Parkinson’s sufferers worldwide."